Breaking News Instant updates and real-time market news.

CYTK

Cytokinetics

$7.39

-0.165 (-2.18%)

07:56
12/10/18
12/10
07:56
12/10/18
07:56

Cytokinetics presents new data at International Symposium on ALS/MND

Cytokinetics announced that new data were presented at the International Symposium on ALS/MND, including patient baseline characteristics and demographics from FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv in patients with ALS. In addition, posters presented at the conference contained data from an analysis of the correlation between slow vital capacity, or SVC, measured at home and in the clinic in FORTITUDE-ALS, additional analyses from VITALITY-ALS, the Phase 3 clinical trial of tirasemtiv in patients with ALS, new results from IMPACT ALS, a patient and caregiver survey conducted by The ALS Association and funded in part by Cytokinetics, and results from analyses conducted by Origent Data Sciences on the validation of machine learning models to predict ALS disease progression using data from VITALITY-ALS. FORTITUDE-ALS, a Phase 2 clinical trial of reldesemtiv designed to assess the change from baseline in percent predicted SVC and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv in patients with ALS, completed enrollment in November. The trial enrolled 458 patients with ALS from centers in the U.S., Canada, Europe and Australia. Baseline characteristics of patients enrolled in FORTITUDE-ALS are similar to those of other recent large clinical trials in ALS, including BENEFIT-ALS and VITALITY-ALS. Patients enrolled in FORTITUDE-ALS were on average 58.7 years of age, 60.7% male, 8.4 months from diagnosis, 22.9 months from their first symptom and had an average percent predicted SVC of 86.8%. Regarding other therapies for ALS, the majority of patients were taking only Rilutek, while 19 were taking only Radicava, 94 were taking both riluzole and edaravone, and 86 were taking neither. Demographics and baseline characteristics were similar among patients who received riluzole alone, edaravone alone, received both or received neither.

CYTK Cytokinetics
$7.39

-0.165 (-2.18%)

10/05/18
HCWC
10/05/18
NO CHANGE
Target $21
HCWC
Buy
Cytokinetics price target lowered to $21 from $24 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target on Cytokinetics shares to $21 from $24 after partner Astellas reported that both primary and secondary endpoints were not met in a trial of reldesemtiv in COPD patients and another trial testing reldesemtiv in elderly frailty was discontinued. However, omecamtiv drives the "lion's share" of his valuation of Cytokinetics shares, said Pantginis. The analyst, who noted that the omecamtiv mecarbil pivotal programs are progressing as planned, keeps a Buy rating on the stock.
10/05/18
PIPR
10/05/18
NO CHANGE
Target $13
PIPR
Overweight
Piper focus for Cytokinetics remains ALS, SMA after reldesemtiv fails in COPD
After Cytokinetics and partner Astellas announced that reldesemtiv failed in a Phase 2 study in COPD and Phase 1b in frailty, Piper Jaffray analyst Edward Tenthoff noted that he had not valued reldesemtiv in either of these indications. The analyst, who said he remains focused on the indications of Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis, keeps an Overweight rating and $13 price target on Cytokinetics shares.
10/05/18
MSCO
10/05/18
NO CHANGE
Target $10
MSCO
Equal Weight
Cytokinetics' reldesemtiv Phase 2 miss not a surprise, says Morgan Stanley
After Cytokinetics and partner Astellas announced that their Phase 2 study of reldesemtiv in COPD did not meet the primary endpoint and did not demonstrate a significant difference in any secondary endpoints, Morgan Stanley analyst Jeffrey Hung said he was not surprised by the "disappointing" results since Cytokinetics management has been suggesting for at least a month that the results from both COPD and frailty would be used to guide development of another compound rather than reldesemtiv. The upcoming R&D Day will focus on the cardiac muscle franchise, added Hung, who keeps an Equal Weight rating and $10 price target on Cytokinetics shares.
09/21/18
CANT
09/21/18
INITIATION
Target $14
CANT
Overweight
Cytokinetics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Cytokinetics with an Overweight rating and $14 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that "biotech has entered a golden age of innovation and productivity across many therapeutic areas."

TODAY'S FREE FLY STORIES

CRSP

Crispr Therapeutics

$67.31

-1.15 (-1.68%)

19:29
11/20/19
11/20
19:29
11/20/19
19:29
Syndicate
Breaking Syndicate news story on Crispr Therapeutics »

Crispr Therapeutics 4.25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Nov

PFGC

Performance Food Group

$44.66

-0.13 (-0.29%)

19:26
11/20/19
11/20
19:26
11/20/19
19:26
Syndicate
Performance Food Group upsized 10.1M share offering said to price at $44.25 »

Report from Bloomberg. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

INVH

Invitation Homes

$30.05

0.13 (0.43%)

19:10
11/20/19
11/20
19:10
11/20/19
19:10
Periodicals
Breaking Periodicals news story on Invitation Homes »

Invitation Homes stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KRTX

Karuna Therapeutics

$108.42

-15.58 (-12.56%)

19:03
11/20/19
11/20
19:03
11/20/19
19:03
Syndicate
Karuna Therapeutics 2.6M share Secondary priced at $96.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

, GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

18:58
11/20/19
11/20
18:58
11/20/19
18:58
Hot Stocks
Google to limit election ads audience targeting, will prohibit 'deep fakes' »

Alphabet's Google…

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAN

Canaan

$0.00

(0.00%)

18:56
11/20/19
11/20
18:56
11/20/19
18:56
Syndicate
Canaan 10M share IPO priced at $9.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NUAN

Nuance

$16.60

0.11 (0.67%)

, CPRT

Copart

$84.69

-1.64 (-1.90%)

18:51
11/20/19
11/20
18:51
11/20/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Nuance…

NUAN

Nuance

$16.60

0.11 (0.67%)

CPRT

Copart

$84.69

-1.64 (-1.90%)

LB

L Brands

$16.00

-1.19 (-6.92%)

JACK

Jack in the Box

$84.89

-0.08 (-0.09%)

SONO

Sonos

$13.87

-0.635 (-4.38%)

NTGN

Neon Therapeutics

$1.44

-0.04 (-2.70%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

UBER

Uber

$28.02

0.99 (3.66%)

LZB

La-Z-Boy

$36.23

-0.265 (-0.73%)

CUB

Cubic

$73.63

0.8 (1.10%)

NTES

NetEase

$287.68

-1.09 (-0.38%)

OPTN

Optinose

$11.42

0.84 (7.94%)

MTEM

Molecular Templates

$8.28

0.19 (2.35%)

PYPL

PayPal

$104.09

-0.85 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 10

    Dec

  • 21

    Nov

  • 21

    Nov

WNC

Wabash

$15.05

-0.2 (-1.31%)

18:48
11/20/19
11/20
18:48
11/20/19
18:48
Initiation
Wabash initiated  »

Wabash initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$45.51

-0.56 (-1.22%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Allison Transmission initiated  »

Allison Transmission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAV

Navistar

$30.97

-0.97 (-3.04%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Navistar initiated  »

Navistar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCAR

Paccar

$78.85

-0.59 (-0.74%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Paccar initiated  »

Paccar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMI

Cummins

$180.59

-2.36 (-1.29%)

18:46
11/20/19
11/20
18:46
11/20/19
18:46
Initiation
Cummins initiated  »

Cummins initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

VMC

Vulcan Materials

$140.72

-0.485 (-0.34%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Vulcan Materials initiated  »

Vulcan Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$24.18

0.3 (1.26%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Summit Materials initiated  »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

MLM

Martin Marietta

$263.10

1.36 (0.52%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Martin Marietta initiated  »

Martin Marietta initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$31.36

-0.38 (-1.20%)

18:33
11/20/19
11/20
18:33
11/20/19
18:33
Hot Stocks
Tenet General Counsel sells 65K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFPT

Proofpoint

$119.56

1.25 (1.06%)

18:23
11/20/19
11/20
18:23
11/20/19
18:23
Hot Stocks
Proofpoint's Salle sells 10,479 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

18:21
11/20/19
11/20
18:21
11/20/19
18:21
Periodicals
Tiffany gives LVMH access to its books after raised bid, Reuters says »

LVMH (LVMUY) has…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CPRT

Copart

$84.69

-1.64 (-1.90%)

18:05
11/20/19
11/20
18:05
11/20/19
18:05
Earnings
Copart reports Q1 non-GAAP EPS 65c, consensus 59c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 06

    Dec

NTES

NetEase

$287.68

-1.09 (-0.38%)

18:04
11/20/19
11/20
18:04
11/20/19
18:04
Earnings
NetEase reports Q3 adjusted ADS $5.12, consensus $3.12 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

17:58
11/20/19
11/20
17:58
11/20/19
17:58
Periodicals
LVMH, Tiffany in deal talks after LVMH boosts bid, Bloomberg reports »

LVMH (LVMUY) and Tiffany…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$310.82

-1.07 (-0.34%)

17:51
11/20/19
11/20
17:51
11/20/19
17:51
Periodicals
Trump expected to sign bill supporting Hong Kong protesters, Bloomberg reports »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.82

-1.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRPX

Therapix Biosciences

$1.50

-0.13 (-7.98%)

17:49
11/20/19
11/20
17:49
11/20/19
17:49
Hot Stocks
Therapix Biosciences to appeal Nasdaq delisting notice »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$117.84

4.43 (3.91%)

17:47
11/20/19
11/20
17:47
11/20/19
17:47
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

NDAQ

Nasdaq

$105.68

0.52 (0.49%)

17:39
11/20/19
11/20
17:39
11/20/19
17:39
Periodicals
Nasdaq executive Nelson Griggs sees fewer IPOs in 2020, Bloomberg says »

Nelson Griggs, executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.